

Noxopharm Limited (ASX:NOX) | ASX Announcement | 9 September 2021

Noxopharm Updated Corporate Presentation

Sydney 9 September 2021: Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) is pleased to provide an updated non-confidential corporate presentation.

The presentation will be used for the upcoming HC Wainwright & Co 23rd Annual Global Investment Conference which is being held as a virtual event from 13-15 September, 2021.

The conference is an annual event for institutional investors, private equity firms, venture capitalists, industry executives and business development executives.

The presentation focuses on the Company's position in the oncology **space** as having a unique multi-functional drug platform with the potential to assist the annual **multi**-billion **dollar** chemotherapy, **radiotherapy and** checkpoint inhibitor **markets** and the nascent targeted radioligand therapy market.

A recording of the corporate presentation will be made available on the Noxopharm website late next week. <u>www.noxopharm.com</u>

-ENDS-

Graham Kelly, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.

About Noxopharm

Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on the treatment of cancer and cytokine release syndrome (septic shock).

Veyonda[®] is the Company's first pipe-line drug candidate currently in Phase 2 clinical trialling. Veyonda[®] has two main drug actions – a moderating effect on the ceramide/sphingosine-1-phosphate balance and inhibition of STING signalling. Activity against the former target contributes to its dual-acting oncotoxic and immunomodulatory functions designed to enhance the effectiveness and safety of standard oncology treatments, i.e., chemotherapies, radiation therapies and immune checkpoint inhibitors. Activity against the latter target provides an anti-inflammatory effect, as well as contributing to an anti-cancer action, but also potentially blocking septic shock.



Noxopharm is running comprehensive drug discovery programs in both oncology and inflammation, and is the major shareholder of US biotechnology company, Nyrada Inc (ASX:NYR), active in the areas of drug development for cardiovascular and neurological diseases.

To learn more, please visit: <u>noxopharm.com</u>

Investor, Corporate & Media enquiries:	Company Secretary:
Prue Kelly	David Franks
M: 0459 022 445	T: +61 2 8072 1400
<u>E: info@noxopharm.com</u>	E: <u>David.Franks@automicgroup.com.au</u>

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.



H.C. Wainwright 23rd Annual Global Investment Conference 13-15 September 2021

Disclaimer

This presentation has been prepared by Noxopharm Limited (NOX or the Company). It should not be considered as an offer or invitation to subscribe for, or purchase any shares in NOX, or as an inducement to purchase any shares in NOX. No agreement to subscribe for securities in NOX will be entered into on the basis of this presentation or any information, opinions or conclusions expressed in the course of this presentation.

This presentation is not a prospectus, product disclosure document, or other offering document under Australian law or under the law of any other jurisdiction. It has been prepared for information purposes only. This presentation contains general summary information and does not take into account the investment objectives, financial situation and particular needs of an individual investor. It is not a financial product advice and the Company is not licenced to, and does not provide, financial advice.

This presentation may contain forward-looking statements which are identified by words such as 'may', 'could', 'believes', 'estimates', 'targets', 'expects', or 'intends' and other similar words that involve risks and uncertainties. These statements are based on an assessment of past and present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors many of which are beyond the control of the Company, its Directors and management.


Although the Company believes that the expectations reflected in the forward looking statements included in this presentation are reasonable, none of the Company, its Directors or officers can give, or gives, any assurance that the results, performance or achievements expressed or implied by the forward-

looking statements contained in this document will actually occur or that the assumptions on which those statements are based are exhaustive or will prove to be correct beyond the date of its making. Readers are cautioned not to place undue reliance on these forward-looking statements. Except to the extent required by law, the Company has no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation.

Readers should make their own independent assessment of the information and take their own independent professional advice in relation to the information and any proposed action to be taken on the basis of the information. To the maximum extent permitted by law, the Company and its professional advisors and their related bodies corporate, affiliates and each of their respective directors, officers, management, employees, advisers and agents and any other person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation and liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use of or reliance on anything contained in, or omitted from, this presentation. Neither the Company nor its advisors have any responsibility or obligation to update this presentation or inform the reader of any matter arising or coming to their notice after the date of this presentation document which may affect any matter referred to In the presentation.


Veyonda[®] currently is not approved for use in Australia or any other country.





Introducing idronoxil (Veyonda[®])

A novel multi kinase and membrane NAD(P)H-oxidase inhibitor targeting aberrant protein behaviour



Four R&D Businesses in One Company



Cancer treatment enhancement



A revolutionary concept in cancer therapy involving a drug (Veyonda[®]) with multiple mechanisms of action that aims to boost the effectiveness of other standard anti-cancer therapies N. A.

R Q(J

DARRT - radiotherapy

IONIC - checkpoint

inhibitor therapy



Programs

CEP - chemotherapy



LuPIN - radioligand therapy



Cancer treatment enhancement

IONIC

Checkpoint inhibitor therapy

Challenge

- PD-1 inhibitor therapy relies on the presence of effector T-cells to take advantage of drug action
- ~95% of human tumours appear to lack effective immune function ('COLD')

ldronoxil

- Inhibits sphingosine kinase 1, blocking S1P production
- → upregulation of CD4+ and CD8+ T-cells
- → restoration of immune function in tumours ('COLD' to 'HOT')

Phase lb trial

Veyonda + nivolumab

Cohort 1: 15 patients refractory to PD-1 inhibitor therapy

Cohort 2: 15 patients PD-1 inhibitor therapy naive



Rationale

- Sphingosine-1-phosphate (S1P) key regulator of immune cell trafficking
- Most tumours over-express
 S1P
- High to low S1P gradient between tumour and blood causes egress of T-cells

Cancer treatment enhancement

DARRT

External beam radiotherapy

Challenge

- Low-dose EBRT triggers an immune response within single irradiated tumours
- On very rare occasions, that immune response shifts from a local to a systemic level → abscopal response



Idronoxil

- Inhibits autophagy
- Activates immune function



Rationale

- Immune (interferon) response to low-dose EBRT stems from damage to mitochondrial DNA
- That damage is repaired by autophagy
- Blocking autophagy extends the interferon response → augmented abscopal response

Phase II DARRT trial

Multi-national (U.S., Australia, France, Hungary)

~100 patients; prostate, breast, lung cancers refractory to standard therapies

Primary end-points: incidence of abscopal responses (RECIST), PFS



Cancer treatment enhancement

LuPIN

Radioligand therapy

Challenge

- Effectiveness of targeted radiotherapy by radioligands dependent on expression of antigen target on cancer cells
- ¹⁷⁷Lu-PSMA therapy limited by rate of expression of PSMA on prostate cancer cells

Idronoxil

- Blocks cell division (G₂M)
 → greater DNA damage
- Blocks DNA repair (topoisomerases 1 and 2; PARP1) → greater cytotoxicity

LuPIN phase I/II study

- 56 mCRPC patients
- Post-enza/abir and 2x taxanes
- mOS = <u>19.7 months</u>

Rationale

- One strategy is to increase PSMA expression
- Another is to enhance the damage inflicted by the available radioactivity



Cancer treatment enhancement



Chemotherapy

Idronoxil

- Blocks external membrane NADH oxidase function → interfers with protein folding
- Blocks S1P expression → reduction in major pro-survival signaling
- Enhanced ceramide expression → increased prodeath signaling
- Increases immune cell recruitment

Phase Ib CEP-2 trial

IND granted July 2021

Multiple U.S. sites planned

First-line therapy doxorubicin and Veyonda in patients with soft tissue sarcomas



Challenge High rates

High rates of inherent and acquired resistance in most tumour types to cytotoxic chemotherapies due to overexpression of pro-survival mechanisms

Rationale
Priming cytotoxic effects of chemo drugs by reducing

pro-survival signaling


Cancer Research Pipeline

'Helper' growth factor inhibitors



Many cancers, particularly the highly aggressive cancers, coopt supporting healthy cells to supply growth factors that drive cancer cell growth.

Noxopharm has identified a novel family of drugs with potential to block these signals






Cancer Research Pipeline

Brain cancer program

Noxopharm and U.S. National Cancer Institute to Collaborate on Promising New Approach to Treatment of Brain Cancer*

Major discovery by NOX scientists of new family of molecules

- Skilling brain cancer cells directly
- Blocking 'helper' growth signals



*ASX Announcement 9 August 2021



Veyonda®

Septic shock




Challenge

To block the inappropriate hyper-inflammatory response to damage caused by the SARS-CoV-2 virus, without blocking a protective anti-viral immune response

Idronoxil

- Potent inhibitor of cGAS-STING /TBK1 signaling pathway → blocking release of proinflammatpry cytokines
- Upregulates NK and T-cell function



Phase I pilot trial completed

- Hospitalised patients with moderate to severe ARDS requiring supplementary O₂
- Veyonda added to SOC
- Treatment well-tolerated
- 37/38 patients recovered/1 death
- Pro-inflammatory cytokines all contained

Phase 2 randomised controlled study proposed for Veyonda to be tested in hospitalized COVID-19 patients with mild hypoxia.

Anti-inflammatory drug offering broadspectrum cytokine inhibition, but without immune-suppression



pharmorage

Chronic inflammatory diseases/autoimmune diseases

pharmorage

Pharmorage, a collaboration between NOX and Hudson Institute of Medical Research.

Based on identification of a new family of drug compounds with highly selective activity against cGAS-STING/TBK1 signaling*


* ASX: 23 August 2021



STING/TBK1 antagonists now centre of major industry interest as new drug class



(at 8 September 2021)



Anticipated News Flow (next 6 months)

- Progress in IONIC-1, DARRT-2 & CEP-2
- Phase 2 COVID-19 clinical trial update
- Oncology drug pipeline progress
- Pharmorage drug discovery progress



Copyright Noxopharm 2021

Key Metrics



For further information:



info@noxopharm.com



www.noxopharm.com

@Noxopharm

